Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996728 | 0.84 | P2RY12 (0.38) | P2RY12KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3232612 | 0.84 | P2RY12 (0.69) | P2RY12KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3230375 | 0.78 | P2RY12 (0.62) | P2RY12KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4991408 | 0.76 | P2RY12 (0.41) | P2RY12KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL3225595 | 0.72 | P2RY12 (0.52) | P2RY12KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3229240 | 0.71 | P2RY12 (0.59) | P2RY12KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3216575 | 0.71 | P2RY12 (0.69) | P2RY12KDM4EALDH1A1MAPK1CYP2C9 | |
| SCHEMBL3328020 | 0.71 | P2RY12 (0.57) | P2RY12KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3324560 | 0.70 | P2RY12 (1.00) | P2RY12CYP2C9 | |
| SCHEMBL3223687 | 0.69 | P2RY12 (0.87) | P2RY12CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885KDM4E 3186/4885ALDH1A1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.